Roth Capital Estimates Cingulate’s Q1 Earnings (NASDAQ:CING)

Cingulate Inc. (NASDAQ:CING) – Equities researchers at Roth Capital issued their Q1 2026 earnings per share estimates for Cingulate in a report released on Monday, March 31st. Roth Capital analyst B. Pachaiyappan anticipates that the company will earn ($0.48) per share for the quarter. Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($11.69) per share. Roth Capital also issued estimates for Cingulate’s Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.67) EPS and Q4 2026 earnings at ($0.76) EPS.

A number of other analysts have also recently weighed in on CING. Roth Mkm started coverage on shares of Cingulate in a research note on Friday, January 10th. They issued a “buy” rating and a $12.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Cingulate in a report on Thursday, March 6th.

Cingulate Price Performance

NASDAQ CING opened at $4.25 on Tuesday. The firm has a market capitalization of $13.65 million, a price-to-earnings ratio of -0.29 and a beta of -0.83. Cingulate has a 52-week low of $1.80 and a 52-week high of $20.83. The company’s fifty day moving average is $4.26 and its two-hundred day moving average is $4.43.

Institutional Investors Weigh In On Cingulate

Several institutional investors have recently bought and sold shares of CING. AlphaMark Advisors LLC boosted its stake in shares of Cingulate by 50,000.0% during the 4th quarter. AlphaMark Advisors LLC now owns 5,010 shares of the company’s stock worth $25,000 after buying an additional 5,000 shares during the last quarter. Jane Street Group LLC bought a new position in Cingulate in the 3rd quarter valued at about $106,000. Geode Capital Management LLC acquired a new stake in Cingulate during the 4th quarter worth approximately $135,000. Finally, Commonwealth Equity Services LLC lifted its holdings in shares of Cingulate by 281.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 43,022 shares of the company’s stock worth $212,000 after buying an additional 31,746 shares in the last quarter. Institutional investors own 41.31% of the company’s stock.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.